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ABSTRACT
Background: Periodontitis is the most common osteolytic disease that is
characterized by inflammation and bone loss. Although periodontitis can be
initiated by microbial dysbiosis, the net bone loss is due to the uncoupling of bone
formation from resorption, in turn attributed to unresolved inflammatory host
response. Aberrant resolution of inflammation may contribute to many osteolytic
inflammatory diseases, thus there is an urgent need for effective regimens to
promote resolution and restore positive osteogenic coupling. Recently, an
endogenous molecule, DEL-1, has been identified as a homeostatic factor that
restrains osteoclastogenesis, regulates integrin-dependent leukocyte recruitment
during the initiation of inflammation, and promotes the resolution of inflammation.
This study aims to explore the osteogenic role of DEL-1 in bone regeneration
during resolution of periodontitis.
Methods: DEL-1-deficient (Edil3-/-) and -sufficient (Edil3+/+) mice (n=5-6/group)
were subjected to 10-day ligature-induced periodontitis followed by ligature
removal for 5 days to facilitate resolution. Bone gain was quantified
morphometrically and newly regenerated bone was confirmed by modified
Masson’s-trichrome staining. Primary cultures of Edil3-/- and Edil3+/+osteoblastic
progenitors were treated with osteogenic medium and their calcification potential
was determined by Alizarin-Red-S staining (n=4cultures/group). DEL-1 and mutant
versions thereof were tested in vivo and in vitro to identify critical component(s) of
DEL-1 involved in bone regeneration and osteogenic differentiation. The receptor
vi

involved was determined by pull-down assay followed by receptor-knockdown
experiments in osteoblastic progenitors.
Results: After ligature removal, periodontal inflammation was resolved and bone
was regenerated in Edil3+/+ mice but not in Edil3-/- mice (unpaired t-test, P<0.01).
Consistently, Edil3-/-osteoblastic progenitors were defective in calcified nodule
formation. Local gingival injection of DEL-1 in Edil3-/- mice restored bone
regeneration (unpaired t-test,P<0.01). Mechanistic analysis using DEL-1 and
mutants thereof showed that bone regeneration and osteogenic differentiation
were dependent on interactions between the RGD motif on the N-terminal onethird of DEL-1 and the β3-integrin on osteoblastic progenitors. Whereas earlier
studies showed that intact DEL-1 is required for efferocytosis and the emergence
of pro-resolving macrophages, its RGD-containing N-terminal component was
sufficient to promote osteogenic differentiation and bone regeneration.
Conclusions: DEL-1 is shown for the first time to promote bone regeneration
during resolution of periodontitis, a function that might be exploited therapeutically
to treat human periodontitis. This study further provides an effective strategy to
also restore bone that has been destroyed due to other chronic osteolytic diseases.
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CHAPTER 1.

INTRODUCTION

“There may be many ways of treating a disease, but there can be but
one correct diagnosis”
Morton Amsterdam, 1974

1.1 Periodontitis as a dysregulated chronic inflammatory disease
Periodontitis affects 47% of United States adults and is characterized by
inflammation and bone loss (Eke et al., 2015; Graves et al., 2011; Hajishengallis,
2014a; Maekawa et al., 2014a; Shin et al., 2015). Although it was once considered
to be an infectious disease (Mombelli, 2003), recent evidence indicates that
“periodontal pathogens” may actually derive from the commensal microbiota in
which they are normally present albeit in low numbers. It is now believed that
dysregulated periodontal inflammation leads to what has been termed “dysbiosis”
of the subgingival microbiota resulting in outgrowth of the periodontal pathogens
(Darveau et al., 2012; Dutzan et al., 2018; Lamont and Hajishengallis, 2015;
Lamont et al., 2018; Xiao et al., 2017). Dysbiosis represents a state of imbalance
in the relative abundance or influence of species within a microbial community
associated with inflammatory disease (Lamont and Hajishengallis, 2015).
Accumulating evidence indicates a strong association between dysbiosis and the
host microenvironment (Hajishengallis, 2014b; Nassar et al., 2017; Xiao et al.,
2017; Yost et al., 2017). Thus, periodontitis should no longer be considered as an
1

infectious disease in the classical sense, rather, it represents a dysbiotic disease
in which bacteria are required but not sufficient for the disease to progress
(Socransky and Haffajee, 1992).

Recognizing the dysregulated inflammatory

nature of periodontitis opens up new opportunities for the diagnosis, treatment and
long-term management of periodontal disease.
While the evidence in germ-free animal studies reveals that bacteria are
required for the initiation of periodontitis (L. et al., 1980; Rovin et al., 1966), the
progression of periodontal disease and bone loss depends on the host
inflammatory response (Assuma et al., 1998; Hajishengallis, 2014a; Hajishengallis
et al., 2014; Pacios et al., 2015). Even though the host inflammatory response
facilitates the elimination of certain bacteria, the ability to use inflammatory
“byproducts” for anaerobic respiration enhances the growth of others (Nassar et
al., 2017). Specifically, certain types of “inflammophilic” bacteria, such as the
proteolytic and asaccharolytic organisms, can obtain essential amino acids and
iron from degraded collagen and heme-containing compounds (hemopexin,
haptoglobin and hemoglobin) generated during tissue-breakdown mediated by
inflammation (Hajishengallis, 2014b).

The recently formulated polymicrobial

synergy and dysbiosis hypothesis and the ecological plaque hypothesis further
suggest that host inflammation response can serve as a selective environmental
factor which enriches specific pathogenic bacteria (Lamont et al., 2018). Based on
this hypothesis, the unresolved chronic inflammatory periodontal environment may
further provide nutrition that supports the periodontitis-associated biofilm
2

(Hajishengallis, 2014b; Xiao et al., 2017) which in turns facilitates the microbial
dysbiosis and progression of periodontitis.
Over the years, the clinical observation that the rate of disease progression
varies between patients has played a role in the evolution of the terminology used
to classify periodontitis. The nomenclature proposed in the 1999 Classification of
Periodontal Diseases and Conditions renamed what had previously been referred
to as juvenile/early-onset periodontitis as aggressive (AgP), and the more common
adult form of periodontitis as chronic periodontitis (CP) (Armitage, 1999). Although
the distinction between the two forms of periodontitis was thought to be due to
their association with unique bacterial pathogens, more recent evidence
demonstrating their common microbiological, immunologic, and histopathologic
features (Armitage, 2010; Ford et al., 2010; Smith et al., 2010) resulted in a clinical
diagnostic dilemma (Armitage and Cullinan, 2010). Since the declaration of
Human Genome Project in 2003, multiple studies have been conducted to further
evaluate the diseases. Advances in machine-learning algorithms and human
transcriptome analysis, the contribution of host inflammatory response to
periodontitis has been further emphasized in a recent clinical study. Through
cluster analysis of the gingival tissue transcriptome and clinical parameters from
120 patients, limited dissimilarities were observed between established AgP and
CP lesions when patients were classified according the to 1999 criteria (Kebschull
et al., 2013). However, after the authors re-categorized the periodontitis patient
into groups based on gene expression signatures, the authors found a distinct
phenotypic separation between two clusters in whole-mouth periodontal
3

destruction and the subgingival microbial burden (Kebschull et al., 2014). This
finding suggests that there may in fact be distinct host responses that manifest as
phenotypically unique forms of disease and provides clues to identify potential
biomarkers for precision diagnosis in periodontitis.

1.1.1 The role of the host immune response in periodontal homeostasis
and disease
A tooth is a unique organ in the body that penetrates cortical bone and oral
epithelium to erupt into the oral cavity. The non-shedding surface of the teeth
creates a distinct microenvironment for the colonization of diverse microorganisms
which triggered our body to coevolve a unique immune response to interact with
the constant challenge from oral microbiota. In response to the microbiota
challenge, a large population of leukocytes is recruited to the junctional epithelium
area around the tooth, with neutrophils being the most abundant leukocyte (5070% of total) in gingivitis and periodontal disease. Neutrophils can produce a
plethora of antimicrobial peptides and trigger several pro-inflammatory
mechanisms to form the first line of defense against pathogenic insults
(Hajishengallis and Hajishengallis, 2014). However, excessive activation of
neutrophils also has a detrimental effect on periodontium by overproduction of
reactive oxygen species (ROS) which not only kills their target microbes but also
creates damage on the surrounding extracellular tissue (Matthews et al., 2007;
Robinson, 2008). Intriguingly, both insufficient and excessive neutrophils
contribute to the pathogenesis of periodontitis (Darveau, 2010; Deas et al., 2003;
4

Eskan et al., 2012; Hajishengallis and Hajishengallis, 2014; Moutsopoulos et al.,
2014; Nussbaum and Shapira, 2011) suggesting that regulating the neutrophil
homeostasis may be essential to periodontal health for a reason beyond its
antimicrobial functions.
Despite being the most abundant form of circulating leukocytes, neutrophils
are relatively short-lived cells with a half-life range from 8 to 12 hours (Mayadas et
al., 2014) and can be rapidly replenished by granulopoiesis and egress of
neutrophils from bone marrow and peripheral blood vessels, respectively
(Edwards, 1994). The ability of human body to maintain a balance between
neutrophil production and turnover, while adapting to environmental challenges,
implies a homeostatic process for the real-time detection and feedback on the
numbers of neutrophils (Mayadas et al., 2014). Ley and colleagues had identified
a neutrophil rheostat (neutrostat) that senses neutrophil recruitment and clearance
in tissue and regulates neutrophils production in the bone marrow through a
negative-feedback loop involving a granulopoietic cytokines cascade, including
interleukin-23 (IL-23), interleukin-17 (IL-17) and granulocyte-colony stimulating
factor (G-CSF) (Hajishengallis and Korostoff, 2017; Stark et al., 2005). Under
steady-state conditions, senescent and apoptotic neutrophils are engulfed by
tissue macrophages, which then induce anti-inflammatory signals via expression
of peroxisome proliferator-activated receptor γ (PPAR γ) and liver X receptor
(LXR). These anti-inflammatory signals, in turn, reduce the steady-state production
of IL-23 by macrophages. IL-23 is a well-established inflammatory cytokine that
induces IL-17 productions by T cells that in turn further induce the production of G5

CSF by stromal cells, driving granulopoiesis and inflammation (Mayadas et al.,
2014). When neutrophils cannot transmigrate to peripheral tissue, such as in
leukocyte adhesion deficiency type I (LAD-I), this regulatory circuit breaks down,
and may in part explain the unrestrained expression of IL-23 and the downstream
cytokines IL-17 and G-CSF in the periodontal tissue (Moutsopoulos et al., 2014).
The local overproduction of IL-17 causes inflammation that leads to bone loss and
bacterial outgrowth (Hajishengallis and Korostoff, 2017; Moutsopoulos et al.,
2014). The concept that LAD-I periodontitis is driven by overactivation of the IL23/IL-17 axis has led to a successful anti-IL-23 host-modulation therapy for the
treatment of periodontitis in an LAD-I patient (Moutsopoulos et al., 2017).
Periodontal health was once considered to represent the complete absence of
an inflammatory infiltrate in gingival tissue. The classic work of Page and
Schroeder first challenges this concept by providing evidence that the infiltration
of neutrophils can be observed in the clinical healthy gingiva in which the initial
accumulation of bacteria biofilm was developed within 2-4 days (Page and
Schroeder, 1976). More recent studies have extended their findings. Neutrophils
were identified in healthy gingiva from germ-free mice (Zenobia et al., 2013).
Contemporary histological studies of healthy periodontal tissue from human
volunteers also reveal a constant numerical density of neutrophils infiltration from
17.7% to 20.6% was maintained in healthy gingiva (Lang and Bartold, 2018). While
it is inevitable to have biofilm accumulation on the non-shedding tooth surface, the
observed inflammatory infiltration in healthy periodontal tissue may be explained
as homeostatic immunity that maintains a balance between the host and the
6

microbiota. The homeostatic periodontal inflammatory infiltrates may be controlled
by multiple negative regulatory mechanisms such as regulatory T cells (Tregs),
and pro-resolving macrophages under conditions of health. Thus, the homeostatic
interaction between a regulated host immune response and the microbiota may
stabilize the periodontium in a state of health while perturbation of the interactions
may result in periodontitis (Douglas, 2018).
Several studies have been recently carried out to dissect causal mechanisms
of periodontitis. Complement is one of the major mechanisms that causes
periodontitis in which the destructive role of complement has been shown by
intervention studies in which pre-existing naturally occurring periodontitis can be
blocked by local C3 inhibition (using the drug compstatin Cp40) in cynomolgus
monkeys (Maekawa et al., 2016). Although complement can play a protective
immune surveillance role in different microbe-driven diseases including
periodontitis, complement can also become an effector of tissue destruction if
overactivated or dysregulated (Ricklin et al., 2016). Moreover, complement may
also be exploited by important periodontitis-associated bacteria (such as
Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, and
Prevotella intermedia) in ways that promote the dysbiotic transformation of the
microbial community (Lamont et al., 2018; Okroj and Potempa, 2018).
Furthermore, complement signaling pathways synergize with toll-like receptors in
eliciting an inflammatory response that leads to alveolar bone destruction (Abe et
al., 2012; Hajishengallis and Lambris, 2011; Hajishengallis et al., 2011; Maekawa
et al., 2014a; Maekawa et al., 2014b). Several studies further identified roles of
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complement beyond the linear cascade of complement activation, specifically
involving cross-talk with other immune and physiological systems, which
collectively coordinate host responses to infection or tissue injury. For instance,
complement can form a barrier against the spread of invading bacteria by
augmenting local clotting (Markiewski et al., 2007) and regulate antigen-presenting
cells and the activation and differentiation of T-cell subsets (Dunkelberger and
Song, 2010; Hashimoto et al., 2010). However, whether these newly identified
mechanisms may also be exploited by periodontitis-associated “inflammophilic”
bacteria to induce periodontal inflammation remain to be identified.
On the other hand, through the use of broad-spectrum antibiotics, Dutzan et al
have shown that counteracting periodontal dysbiosis reduces the ligature-induced
periodontal bone loss and diminishes the expansion of resident memory T helper
17 (Th17) in mice (Dutzan et al., 2018). While the expression of the cytokine
interleukin-17 (IL-17) and expansion of Th17 cells has been previously observed
in the lesion of human periodontitis and ligature-induced experimental periodontitis
(LIP) in mice, Dutzan et al demonstrated that dysregulated IL-17 expression from
Th17 cells triggers periodontal bone loss and that genetic or pharmacological
inhibition of the expansion of Th17 cells ameliorates the LIP-induced periodontal
tissue destruction. Although IL-17 and Th17 cells play an important role in the host
defense by inducing anti-bacterial peptides and recruiting neutrophils to promote
local inflammation (Ishigame et al., 2009; Iwakura et al., 2011), they also contribute
to the pathogenesis of various autoimmune disease as well as periodontitis by
causing prolonged inflammation and tissue damage (Maekawa et al., 2015;
8

Okamoto et al., 2017; Takayanagi, 2012; Zenobia and Hajishengallis, 2015).
Interestingly, unlike other epithelial barriers such as the skin and gut, the gingivaresident Th17 cells can expand, under steady-state conditions, via commensal
colonization-independent mechanisms, such as occlusal loading and tissue
damage during mastication (Dutzan et al., 2017). However, in periodontitis, a
pronounced accumulation of Th17 can be triggered by the dysbiotic oral
microbiota, which results in periodontal tissue destruction in mice and humans
(Dutzan et al., 2018). In periodontitis, the upregulated IL-17 also induces RANKL
expression in osteoblastic cells and periodontal ligament cells which in turn
stimulate osteoclastogenesis leading to enhanced periodontal bone loss
(Tsukasaki et al., 2018).

9

1.2 Bone as a homeostatic tissue
Bone is a masterfully programmed tissue that undergoes frequent renewal and
has a large capacity for regeneration (He et al., 2004; Xiao et al., 2016a). During
adult life, the skeletal mass is sequentially regulated by two key activities occurring
on the same surface: bone resorption by hematopoietic lineage osteoclasts and
bone matrix formation by mesenchymal lineage osteoblasts -- a process termed
remodeling. The group of cells responsible for remodeling is termed the basic
multicellular unit (BMU) (Parfitt, 1994). The BMU is a particular structure around
the bone remodeling sites which is surrounded by a canopy of bone lining
cells/osteoblasts and nearby capillaries. The BMU concept originally included only
osteoclasts and osteoblasts, but over recent years, as more cellular contributors
to remodeling have been identified (such as T-cells, macrophages, osteocytes,
and precursor populations of osteoblasts and osteoclasts), the number of cells in
BMU has expanded and more molecules that regulate the balance within BMU
have been identified (Sims and Martin, 2015).
Under healthy physiological conditions, an episode of bone resorbed by
osteoclasts is precisely restored by the recruited osteoblastic lineage cells which
differentiate and deposit just enough new bone at the same place, a homeostatic
process referred to as coupling (Parfitt, 1982; Xiao et al., 2016a). While the
lifespan of osteoclasts lasts only 2 weeks, the lifespan of active osteoblasts lasts
around 3 months (Manolagas, 2000). It has long been of interest to understand
how these two distinct cell types, on the same bone surface but at different times,
could be linked so that their activities are balanced (Sims and Martin, 2015). Early
10

studies using timed fluorochrome labeling histological sections identified that bone
resorption in iliac crest trabecular BMUs of adult human bone takes approximately
3 weeks (Eriksen et al., 1984b), the formation response 3-4 months (Eriksen et
al., 1984a), and between the two activities there is a poorly understood “reversal
phase” (Van Tran et al., 1982) of approximately 5 weeks (Eriksen et al., 1984b).
In rodents, although the duration of this sequence is compressed, a time delay
between resorption and formation still exists: in rat alveolar bone the reversal
phase lasts approximately 3.5 days (Vignery and Baron, 1980). These time
windows also vary with site, skeletal health, and treatment (Jensen et al., 2014).
The increased duration or arrest of reversal phase is also observed in
postmenopausal osteoporosis which associates with decreased trabecular bone
volume and osteoid formation (Andersen et al., 2013). Exploring the mechanisms
by which coupling signals overcome the time delay between bone resorption and
bone formation may provide clues in facilitating bone regeneration during
resolution of periodontitis.
Under inflammatory conditions, cytokines, such as TNF, RANKL, IL-1, IL-6,
and IL-17, promote osteoclastogenesis or activate osteoclasts to resorb bone
(Boyle et al., 2003; Graves, 2008; Okamoto et al., 2017) but an equivalent amount
of bone formation does not occur, so that resorption and formation are uncoupled
(Graves et al., 2011; Parfitt, 1982). The inflammation may affect bone formation
through several mechanisms. First, it may stimulate the death of bone lining cells
and reduce the number of available progenitor cells that can form new bone (AlMashat et al., 2006; Liu et al., 2006). Furthermore, cytokines associated with
11

inflammation may inhibit the differentiation of osteoblastic progenitors and thus
limit bone formation (Behl et al., 2008; Diarra et al., 2007). The third mechanism
is reduced bone matrix production due to the impact of inflammatory mediators
(Graves et al., 2011; Liu et al., 2006; Tarapore et al., 2016). On the contrary, bone
formation may be facilitated through mechanisms that inhibit osteoclast activation
(Boyle et al., 2003), sustains the number of available osteogenic progenitors (Stein
and Lian, 1993), promotes their differentiation that recapitulates the steps of bone
formation during development (Ferguson et al., 1999), and facilitates their
deposition of osteoid matrix proteins (Owen et al., 1990) during resolution of
inflammation (Claudino et al., 2010; Dresner-Pollak et al., 2004; Stein and Lian,
1993; Xu et al., 1995)

12

1.3 Resolution of inflammation: a new therapeutic frontier
The correlation between the resolution of inflammation and periodontal bone
regeneration has been clinically observed more than 20 years ago, where patients
with compromised resolution (higher bleeding on probing index) following
periodontal phase I therapy show poorer bone regenerative outcome (Tonetti
1993). Resolution is an active process which starts during inflammation. During
the progression of inflammatory events, platelet-leukocyte interactions elicit the
formation of lipoxins A4 and B4, which serve as “stop signals” by blocking further
neutrophil recruitment from the post-capillary venules. This stop in further
neutrophil recruitment to tissues is also temporally associated with a switch of the
families of lipid mediators generated from eicosanoids to resolvins of the E and D
series as well as protectins (Serhan and Savill, 2005). The resolvins D1, D2, and
E1 and lipoxins A4 and B4 further promote the ability of tissue macrophages to
uptake apoptotic neutrophils in a non-phlogistic process termed efferocytosis.
Efferocytosis in turn causes a switch in macrophage phenotype from inflammatory
to pro-resolving and pro-regenerative, i.e., capable to further promote resolution
of inflammation and tissue repair (Back et al., 2014; Gyurko and Van Dyke, 2014;
Kourtzelis et al., 2017; Recchiuti, 2013). Inability to adequately resolve acute
inflammatory condition leads to the development of maladaptive immunity and
result in chronic inflammatory diseases (Fullerton & Gilroy, 2016). While current
drug development mainly focusses on anti-inflammatory approaches, the proresolution strategies intrinsically afford greater scope in treating chronic
inflammatory diseases in which these strategies shorten the time required to
13

restore tissue integrity and function. However, evidence to date suggests that
resolution could be tissue- and stimulus-specific, thus, developing a locally
deliverable drug may provide an optimal therapeutic effect for the regionally
dysregulated chronic inflammatory disease.

1.3.1

Resolution and Integrins

Timely resolution of an inflammatory response is critical to prevent unnecessary
tissue damage and promote reconstitution of tissue integrity after acute
inflammatory insult (Kourtzelis et al., 2019). Resolution is a tightly regulated
process which restricts further leukocytes influx, promotes their clearance from the
tissue and restores functional tissue homeostasis (Fullerton and Gilroy, 2016).
While dysregulated resolution may contribute to many chronic inflammatory
diseases, current regimens to promote resolution are limited.
Recently, a new perspective to regulate resolution has been proposed through
mechanisms associated with integrins. Integrins are cell surface heterodimeric
receptors that regulate cell-to-cell
and

cell-to-extracellular

matrix

interactions. The integrin family

Figure 1. The contribution of integrins to
the onset and resolution of inflammation
(Kourtzelis et al., 2017).

comprises

24

members

mammals,

formed

by

in
the

combination of 18 α and 8 β
subunits (Kourtzelis et al., 2017)

(Fig. 1). These integrins play a critical role in a wide range of important immune
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processes, from the initial recruitment of leukocyte into the sites of inflammation
to the clearance of apoptotic cell material in the context of the resolution of
inflammation. Recently, an endogenous molecule, DEL-1, has been identified as
a homeostatic factor that restrains osteoclastogenesis and β2 integrin-dependent
leukocyte recruitment during the initiation of periodontal inflammation (Eskan et
al., 2012; Lee et al., 2017; Maekawa et al., 2017) and promote macrophage
efferocytosis to facilitate the resolution of inflammation (Kourtzelis et al., 2019).
Unlike other endogenous regulators of the leukocyte adhesion cascade, such as
pentraxin-3 which is produced by the inflammatory cell itself (Maina et al., 2009),
DEL-1 is specifically secreted by cells in the tissue (such as endothelial cells)
which indicates its ability to regulate local chronic inflammatory responses and
restore functional homeostasis in tissues that express it (Eskan et al., 2012). Here,
we present evidence for a novel integrin-dependent mechanism of DEL-1 by which
promotes formation of new bone during resolution of periodontitis.

1.3.2

The role of DEL-1 during resolution

DEL-1 is an extracellular matrix protein encoding three Notch-like EGF repeats,
an RGD motif, and two discoidin I-like domains (Hidai et al., 1998; Oshima et al.,
2014) (Fig. 2). It was first discovered by its unique genetic locus and identified in
an enhancer trap event during embryonic vascular development (Hidai et al., 1998;
Penta et al., 1999).
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Figure 2. The domain structure of endogenous DEL-1 (Oshima et al., 2014).

The expression of DEL-1 in gingiva is known to be physiologically
downregulated during acute periodontal inflammation which allows leukocyte
extravasation. (Eskan et al., 2012). Moreover, DEL-1 is downregulated with aging
in mice and humans (Eskan et al., 2012; Folwaczny et al., 2017).To study the
function of DEL-1 in tissue, a DEL-1-LacZ knock-in transgenic mice model was
developed (Yang et al., 2014). In this transgenic, the LacZ gene is inserted into
the normal position of DEL-1 and is controlled by the DEL-1 promoter. When bred
to homozygosity, the animal becomes functionally deficient in DEL-1. These DEL1-deficient mice are fertile and live under normal lifespan without apparent
vascular or skeletal abnormality. However, these mice do exhibit an accelerated
periodontal aging phenotype in which the spontaneous periodontitis starts to
develop at a young age in comparison with their wild-type littermates (Eskan et al.,
2012).
The genetic deficiency of DEL-1 not only leads to excessive leukocyte infiltration
in mouse gingiva but also causes IL-17-dependent periodontal tissue damage
(Eskan et al., 2012; Khader, 2012). IL-17 has been shown to downregulate DEL1 expression in endothelial cells, but this inhibitory action can be counteracted by
resolvins D1 and D2, specialized pro-resolving mediators (SPMs) that promote
resolution (Maekawa et al., 2015). Recently, Kourtzelis et al further identified a
non-redundant role of DEL-1 to promote resolution of acute inflammation through
facilitating macrophage efferocytosis of the apoptotic neutrophils through the
binding of its RGD motif to the β3 integrin on the surface of macrophages and the
binding of its discoidin I-like domains to the “eat-me” signal phosphatidylserine on
16

the surface of apoptotic cells (Kourtzelis et al., 2019). Using two different mouse
inflammation models (monosodium urate (MSU) crystal-induced peritonitis and
ligature-induced periodontitis), Kourtzelis et al moreover showed that while
endothelial cell-produced DEL-1 was associated with the inhibition of leukocyte
recruitment, macrophage-produced DEL-1 was associated with efferocytosis and
inflammation resolution. In this regard, DEL-1-facilitated efferocytosis triggered
liver X receptor (LXR) signaling pathway in macrophages and transformed its
phenotype to a pro-resolving macrophage which promotes the resolution of
inflammation. The findings regarding the compartmentalized functions of DEL-1
have revealed a novel location-dependent homeostatic principle (‘location
principle’) in the spatial regulation of the immune response by DEL-1 (Kourtzelis
et al., 2019).
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1.4 Current gaps in periodontal therapy
Although the classifications of periodontitis have been constantly changed every
one or two decades, the way we treat periodontitis nowadays is still no different
from what it was 50 years ago. The discrepancy between diagnosis and treatment
lies in the lack of understanding on its pathophysiology and how the functional
tissue homeostasis is restored during resolution so that a precise evaluation on
the prognosis and a corresponding target therapy cannot be achieved. Current
approaches for treating periodontitis focus on removing biofilm from the tooth
surface; however, host responses to the treatment vary. While some patients show
rapid resolution and reparative bone formation after therapy, others resolve slowly
or fail to do so (Jin et al., 2000; Lindhe et al., 1985; Rakic et al., 2018; Van der
Weijden and Timmerman, 2002). Therefore, understanding homeostatic
mechanisms that facilitate effective bone regeneration following the treatment of
periodontitis is a critical and unanswered issue.
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1.5 Hypothesis
We established an in vivo model to investigate quantifiable bone formation
during resolution of ligature-induced periodontitis in mice. In this model, we found
that DEL-1 expression is upregulated in resolving gingiva as compared to its
baseline expression in healthy gingiva. The upregulation of DEL-1 in resolving
gingiva suggests a significant physiological role of DEL-1 during the resolution,
which we investigated DEL-1 by using DEL-1-deficient (Edil3-/-) mice. Interestingly,
whereas wild-type littermate controls regenerated bone during resolution, DEL-1deficient (Edil3-/-) mice failed to regenerate bone during the resolution phase. This
deficiency in forming new bone was restored by local injection of recombinant
DEL-1 during the resolution phase in Edil3-/- mice. Based on these findings, we
hypothesized that DEL-1 may act to promote osteogenesis during resolution of
periodontitis.
While the role of DEL-1 in promoting osteogenesis in vivo has not been
previously addressed, the unique RGD motif on DEL-1 (Schurpf et al., 2012)
provides clues for its potential osteogenic effect. Recent studies have shown that
osteoblastic progenitors can be directed to differentiate into osteoblasts and
promote mineralization by the ligation of its cell-surface integrins by extracellular
matrix proteins with RGD motif (Sens et al., 2017). Whereas intact DEL-1 may be
required for efferocytosis and the emergence of pro-resolving macrophages
(Kourtzelis et al., 2019), if the hypothesized osteogenic effect of DEL-1 depends
on its RGD motif, then the RGD-containing N-terminal segment of DEL-1 may be
sufficient to promote osteogenic differentiation and bone regeneration. This study
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proposes to characterize a unique function of DEL-1 in the context of the resolution
of periodontal inflammation. Specifically, we hypothesize that DEL-1 promotes
osteogenic differentiation to restore functional tissue homeostasis during
resolution of periodontitis.

Figure 3. Schematic representation of the hypothesis. This study focuses on
interrogating the osteogenic role of DEL-1 during resolution of periodontitis. While it has
been shown that DEL-1 can inhibit bone resorption on osteoclasts (Shin et al., 2015), we
hypothesized that DEL-1 can directly promote osteogenic differentiation on osteoblasts,
and this function promotes formation of new bone during resolution.
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Chapter 2. Material and Methods
2.1 Study design
The objective of this study was to understand the mechanisms by which DEL-1
regulates osteogenesis and test its capacity to promote bone regeneration during
the resolution phase of ligature-induced periodontitis in mice. All animal
procedures were performed according to protocols reviewed and approved by the
Institutional Animal Care and Use Committees (IACUCs) of the University of
Pennsylvania. In vivo experiments in mice involved at least five mice per group
including both sexes (determined by GraphPad StateMate power analysis for
P=0.05 and a power of 0.80). No animals were withdrawn from the studies
according to predetermined criteria in the IACUC protocols or were excluded from
any of the analyses. All the in vitro and in vivo experiments were performed two or
more times for verification.

2.2 Animals
Mice were maintained in individually ventilated cages and provided sterile food and
water ad libitum under specific pathogen-free conditions. They were used for
experiments when they were 8 to 10 weeks old. The generation of C57BL/6 DEL1-deficient (Edil3 -/-) mice was previously described (Choi et al., 2008). Wild-type
C57BL/6 mice were purchased from Jackson Laboratory and were bred with DEL1-deficient mice to establish Edil3+/+ and Edil3-/- littermate controls.
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2.2.1

Resolution of ligature-induced periodontitis in mice

Groups of 8-week-old Edil3+/+ and Edil3-/- littermate mice were subjected to
experimental periodontitis. A 5-0 silk ligature was tied around the maxillary left
second molar for 10 days to induce periodontitis in mice. The contralateral tooth
was kept unligated as baseline control. In the resolution group, the ligatures were
removed at day 10 to allow 5 days of resolution of inflammation, and the mice were
sacrificed at day 15. Periodontal bone loss was assessed morphometrically in
defleshed maxillae using a dissecting microscope (40x) fitted with a video image
measurement system (Nikon Instruments). Specifically, the CEJ-ABC distance
was measured on six predetermined points on the ligated second molar and the
affected adjacent regions (Abe and Hajishengallis, 2013). Bone loss was
calculated by substracting the six-site total CEJ-ABC distance of the ligated side
of each mouse from the six-site total CEJ-ABC distance on the contralateral
unligated side. The data was further transformed to indicate bone regeneration (or
loss; negative value) by substracting the value obtained from the bone loss
generated at 10 days of ligature.

2.2.2

DEL-1 and mutants thereof

To enhance the half-life of recombinant DEL-1 protein, our laboratory has
synthesized the chimeric human DEL-1 with the Fc component of human IgG
(DEL-1-Fc) (Czajkowsky et al., 2012; Shin et al., 2015). Mutants of DEL-1-Fc
including a single amino acid substitution from Glu [E] to Asp [D] in the RGD motif
(DEL-1[RGE]-Fc), an N-terminal segment containing only the EGF repeats (DEL22

1-[E1-3]-Fc) were also generated to assist further mechanistic investigation in vivo
and in vitro.

It should be noted that DEL-1 performs similar functions (e.g.,

inhibition of neutrophil transmigration and osteoclastogenesis) across species,
probably because human DEL-1 has 96% and 99% a.a. sequence identity with its
mouse and cynomolgus counterparts, respectively (Choi et al., 2008; Choi et al.,
2015; Eskan et al., 2012; Maekawa et al., 2015; Shin et al., 2015).

2.2.3 Intervention experiments in mice
Groups of 8-week-old Edil3-/- mice of both sexes were subjected to experimental
periodontitis for 10 days. The ligatures were removed at day 10 to allow resolution
of periodontal inflammation. These mice were subsequently daily microinjected (at
days 10 to 14) with Fc control (0.31 µg; 12.3 pmol, AG714; Millipore) and various
DEL-1-Fc mutants at molar equivalents: Intact DEL-1-Fc (1 µg), DEL-1[RGE]-Fc
(1 µg), and DEL-1[E1-3]-Fc (0.54 µg). Microinjections were performed into the
palatal gingiva between first and second maxillary molars using a 33-gauge
stainless steel needle attached to a micro syringe (Hamilton).

2.2.4 Histological analysis
Coronal sections of the ligated molars were prepared and stained with modified
Masson's trichrome staining (# ab150686; Abcam), which stains mature (old) bone
and connective tissue in blue; immature new bone (osteoid) and collagen in red
(Asonova and Migalkin, 1996).
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2.3 In vitro osteogenesis
Osteoblastic progenitors. Primary cultures of osteoblastic progenitor cells
were derived from 3-day-old Edil3+/+ and Edil3-/- mice by digesting calvarias in
phosphate-buffered saline (PBS) containing 0.1% collagenase (Worthington
Biochemical) and 0.2% dispase (Roche Chemical Science) for 20 min at 37 0C. The
digestion was sequentially performed three times and cells isolated from last two
digestions were cultured in α-MEM supplemented with 10% FBS as primary
osteoblastic progenitors (Takedachi et al., 2012). The murine osteoblastic
progenitor cell line (MC3T3-E1 Subclone 4) was purchased from ATCC (#CRL2593, Rockville, MD) for receptor knockdown experiments. All cells were
maintained in α-MEM supplemented with 10% FBS, penicillin (50 U/ml) and
streptomycin (50 mg/ml) prior to further experiments.
Osteogenic differentiation assay. The osteoblastic progenitors were also
cultured in osteogenic differentiation medium (contains 50 mg/ml ascorbic acid and
10 mM β-glycerophosphate in α-MEM supplemented with 10% FBS) for 12 to 18
days. The medium was changed every three days. Mineralized bone nodules were
detected with Alizarin Red S staining on day 12 or day 18 of osteoblastic
differentiation. The cultures were washed twice with PBS, fixed with 4% PFA-PBS
for 15min and washed again with PBS and sterile water. Alizarin red staining was
performed by covering the cells with 2% Alizarin red S solution (pH 4.1-4.3) for 45
min and then rinsing extensively with water. The plates were scanned, and the
calcified nodules were quantified using the Image J software (https://
imagej.nih.gov/ij).
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2.3.1
Real-time and quantitative real-time polymerase chain reaction
(qPCR) analysis
Following in vivo or in vitro treatments, total RNA was extracted from gingiva tissue
and in vitro cultured cells using Trizol reagent (Invitrogen) according to the
manufacturer’s instruction. Reverse-transcription was carried out using 500ng of
total RNA and High-Capacity RNA-to cDNA kit (#4387406, Thermo Fisher
Scientific). The level of gene expressed was examined using Taqman Fast
Advanced Master Mix (#4444557, Thermo Fisher Scientific) according to the
manufacturer’s protocol.
The primers used for mouse gene detection include: Itgb3(#Mm00443980_m1),
Edil3(#Mm01291247_m1), Runx2(#Mm00501584_m1),
Bglap(#Mm03413826_mH), Gapdh(#Mm99999915_g1)

2.3.2

Western blot analysis

Following treatment, cells were lysed with RIPA buffer supplemented with protease
and phosphatase inhibitor, then subjected to SDS-PAGE. Total protein content
was quantified and transferred onto a polyvinylidene difluoride (PVDF) membrane
(Immobilon-P; Millipore,MA), blocked with 5% non-fat milk in Tris-buffered saline
containing 0.05% Tween 20 (TBST), probed with primary antibody (4°C overnight),
and incubated with corresponding secondary antibodies (room temperature, 1
hour). After enhanced chemiluminescence (ECL) using Luminata Forte Western
HRP substrate (Millipore), the protein bands were imaged using the FlourChem M
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imaging system (ProteinSimple) and the band intensities were quantified with the
Image J software.

2.3.3

Pull-down assay

Pull-down experiments were performed using Pull-down polyHis protein:protein
Interaction kit (#21277; Pierce,IL) as per the manufacturer’s instruction. Briefly,
MC3T3-E1 cells were cultured in a T75 flask and incubated at 37°C for 48 h. After
reaching confluence, the cells (~1 x107) were released by trypsin digestion,
neutralized with medium containing 10% FBS, washed with phosphate buffered
saline (PBS) and collected by centrifuging at 500 x g for 5 min. The cells were then
lysed, and the cell membrane proteins were isolated using cell fractionation kit
(#9038; Cell Signaling Technology). The pull-down washing solution was prepared
by mixing 1:1 proportion of TBS: Pierce Lysis Buffer and imidazole stock solution
(4M) to adjust to a final concentration of 10 mM imidazole. Cobalt chelate resin (50
μL) was added to the spin column and equilibrated with washing solution.
Subsequently, the resin was incubated with 300 μL of histidine-tagged DEL-1-Fc
(100 μg) at 4°C with gentle rocking. After incubation for 1 h, the DEL-1-Fc-bonded
resins were collected in the spin column by centrifugation at 1250 x g for 1 min,
washed 5 times with washing solution, and incubated with the cell membrane
lysate of MC3T3-E1 cells for 4 h at 4°C. After washing for additional 5 times, the
bound proteins in the resin were eluted with elution buffer (imidazole, 290 mM).
The eluted sample was resolved using SDS-PAGE and the captured molecules
were identified by immunoblotting with appropriate antibodies, including rabbit anti26

mouse β3 integrin (#13166, CST), β1 integrin (#34971, CST), DEL-1 (#12580-1AP, Proteintech), and HRP conjugated murine anti-6x-His tag antibody (#R93125, Invitrogen).

2.3.4

Receptor knockdown by specific shRNA

To knock down integrin β3 in MC3T3-E1 cells, we used the shRNA pLKO.1
construct specific for integrin β3 (TRCN0000009620; Sigma) and, as a control,
empty pLKO.1 vector (SHC001; Sigma). Knockdown efficiency was confirmed by
qPCR analysis. For transfection of shRNA, cells were plated in 6-well plates at a
density of 1.5x105 cells/well, cultured until 70%-80% confluence and transfected
with vectors using FuGENE HD® (Roche) transfection reagent following a ratio of
3:1 (volume of FuGENE: µg of DNA). Cells were maintained in nonselective
medium for 48 hours post-transfection, and then changed to selection medium
containing Puromycin (2 µg/ml). The use of selection medium was continued for 3
weeks with frequent changes of medium to eliminate dead cells and debris until
distinct colonies could be visualized. The adherent cells were further released by
trypsin digestion and plated in T75 flasks for further propagation. The transfected
cells were maintained under selection medium (contained Puromycin 2 µg/ml) for
the duration of the experiments.

2.4 Statistical analysis
Data were evaluated with one-way ANOVA and the Dunnett’s multiple-comparison
test with the InStat program (GraphPad Software). Where appropriate (comparison
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of two groups only), two-tailed t tests were performed. P value <0.05 was
considered to be statistically significant.
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Chapter 3. Results
3.1

DEL-1 is upregulated during resolution of periodontitis

DEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in
experimental periodontitis in mice and non-human primates (Shin et al., 2015).
Here, we focused on a new function of DEL-1 in the context of periodontitis
resolution. Periodontal inflammation resolution was initiated by removing ligatures
from C57BL/6 wild-type mice which previously received ligature-induced
periodontitis for 10 days (Fig.4A). The bone levels (CEJ-ABC distance values)
measured after resolution at day 15 were transformed to indicate bone gain relative
to a baseline set by the bone levels measured at day 10 after ligature-induced
periodontitis (Fig.4B-D). Ligature removal at day 10 resulted in bone gain 5 days
later, whereas the continuous presence of ligatures for 15 days caused further
bone loss as compared to baseline (Fig.4D).
The expression of endogenous DEL-1 in gingiva is known to be significantly
reduced and downregulated during aging and periodontal inflammation (Eskan et
al., 2012). Through quantitative real-time PCR of dissected mouse gingiva, we
showed significant upregulation of DEL-1 in resolving gingiva in comparison with
the uninflamed baseline (P<0.05 vs. non-ligature site; Fig. 4E). We reasoned that
the upregulated expression of DEL-1 in periodontal inflammation resolution may
be involved in the observed bone gain.
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Figure 4. Upregulation of DEL-1 and bone gain during resolution. (A) Model
description. (B) Measurement of bone heights (distance from cement-enamel junction to
alveolar bone crest; CEJ-ABC) in groups of mice (8- to 10-week old) after 10- or 15-days
ligature (10d L or 15d L) or after 10 days ligature followed by 5 days without ligatures to
enable resolution (10d L+5d R). (C) Data from B were transformed to indicate bone loss
in ligated (L) sites versus un-ligated (U) contralateral sites. (D) Data from C were
transformed to indicate bone regeneration (or loss; negative values) relative to the 10d L
group which served as the baseline. Data are means ± SD (n=9-11 female or male mice
per group). ****P<0.0001 (One-way ANOVA and Dunnett’s post-test). (E) Healthy gingiva
and gingiva during the resolution phase were dissected from mice and assayed for DEL1(Edil3) gene expression analysis using qPCR. Data are mean± SD (n= 5 mice/group)
***P < 0.001 (Two-tailed unpaired t-test).
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3.2

DEL-1 promotes bone regeneration during resolution of
periodontitis

To investigate whether the observed bone gain involved formation of new bone,
we performed histological analysis using modified Masson’s trichrome staining
which stains newly formed osteoid in red and old bone in blue. We then confirmed
there was indeed newly regenerated bone on C57BL/6 DEL-1-sufficient (Edil3+/+)
mice during resolution of ligature-induced periodontitis (Fig.5A). On the contrary,
Edil3-/- mice failed to generate new bone although the ligatures were removed
(Fig.5B). Reduced coronal periodontal attachment but increased gingival swelling
was also observed in the resolving phase of Edil3-/- mice in comparison with that
observed on Edil3+/+ littermates (Fig.5B). The difference in bone regeneration was
quantified morphometrically; Edil3-/- mice significantly lost ability to regenerate
bone during resolution phase (P<0.05 vs. Edil3+/+ littermates; Fig.6).
To test whether the deficiency of DEL-1 could be rescued through replenishing
the DEL-1 during resolution, we performed daily microinjection of DEL-1-Fc (1µg)
versus equal molar amount of Fc control (0.31µg) during resolution phase in Edil3/-

mice. As expected, we successfully restored the bone gain in Edil3-/- mice by

supplying DEL-1-Fc during resolution phase (P>0.05; Fig.6). To interrogate
whether the observed bone gain was contributed by newly regenerated bone, we
performed a split mouth experimental design (Antczak-Bouckoms et al., 1990) by
performing 10 days LIP and 5 days resolution on both left and right side on the
same Edil3-/- mice, and locally inject Fc control on the left side and DEL-1-Fc on
the right during resolution. The trichrome staining further showed the injection of
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DEL-1-Fc not only resolved the gingival swelling but also restored periodontal
attachments and new bone formation on Edil3-/- mice (Fig. 5C, D). In sum,
endogenous DEL-1 plays a critical role in formation of new bone during periodontal
inflammation resolution which restores functional homeostasis. In contrast, DEL-1
deficiency results in impaired bone regeneration DEL-1 which is restorable through
local delivery of DEL-1-Fc during the resolution phase.
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Figure 5. DEL-1-deficient mice fail to regenerate bone during the resolution phase,
and the deficiency in bone regeneration can be restored by injecting DEL-1-Fc.
Coronal sections of the resolution of ligated molars on (A) DEL-1-sufficient (Edil3+/+) and
(B) DEL-1-deficient (Edil3-/-) mice were prepared for histological analysis. Sections from
the same Edil3-/- mice receiving LIP and resolution on both side but receiving local injection
in a split mouth design by injecting Fc control on the left side (C) and DEL-1-Fc on the
right (D). Sections were stained with modified Masson's trichrome staining, which stains
mature (old) bone blue and immature new bone (osteoid) red. Shown are representative
images (scale bars, 100 μm) and insets (scale bars, 25 μm) from resolution sites. NB,
new bone; OB, old bone; PDL, periodontal ligament; T, tooth; P, Periodontal pocket.
33

3.3

DEL-1 domains and motifs involved in osteogenesis

We next examined the role of DEL-1 and its structural features in bone
regeneration. To this end, we microinjected mutants of DEL-1-Fc into gingiva
during resolution, including a single amino acid mutation in the RGD motif (DEL1[RGE]-Fc), and an N-terminal segment containing only the EGF repeats (DEL1[E1-3]-Fc). Interestingly, the single amino acid mutation on the RGD motif
completely abolished its ability to promote bone regeneration on intact DEL-1-Fc,
and the N-terminal segment of DEL-1 (DEL-1[E1-3]-Fc) was sufficient to induce
bone regeneration (P<0.05 vs. Fc control; Fig.6). This finding suggests that DEL1 promotes bone regeneration through a mechanism dependent on its RGD motif.
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Figure 6. DEL-1 promotes bone regeneration during resolution in an RGDdependent manner. Edil3+/+ and Edil3-/- littermates (8- to 10-week old) were subjected to
ligature-induced periodontitis for 10 days followed (or not) by 5 days resolution, with or
without local treatment with DEL-1-Fc (1 μg) or equal molar amounts of Fc control or
mutants. Treatments were performed daily (days 10-14) in Edil3-/- mice. CEJ-ABC data
were transformed to indicate bone regeneration as outlined in Fig.1. Data are means ± SD
(n=5-9 female or male mice per group). ***P<0.001, ****P<0.0001. WT, Edil3+/+ mice; KO,
Edil3-/- mice; NS, not significant (One-way ANOVA and Dunnett’s post-test for comparing
treatments to untreated KO; two-tailed unpaired t-test for the other indicated comparisons,
e.g., WT mice with resolution vs. WT mice without resolution).
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3.4

DEL-1 promotes osteoblast differentiation through its RGD motif

The ability of DEL-1 to promote bone regeneration could be explained by direct
action on osteoblastic cells or indirectly by DEL-1 enhancement of β3 integrinmediated efferocytosis which promotes inflammation resolution as demonstrated
recently (Kourtzelis et al., 2019) thus enhancing osteoblast function and bone
formation. The latter mechanism is consistent with the RGD motif requirement as
the efferocytic function of β3 integrin depends on this motif (Hanayama et al., 2004;
Kourtzelis et al., 2019). However, efferocytosis also requires the involvement of
the C-terminal discoidin-like domains of DEL-1, which bind phosphatidylserine, a
major ‘eat-me’ signal on the apoptotic cell surface (Hanayama et al., 2004;
Kourtzelis et al., 2019). To interrogate whether DEL-1 can directly interact with
osteoblastic progenitors to promote bone gain, we compared the osteogenic
capacity of DEL-1 on cultured Edil3-/- versus Edil3+/+ primary osteoblastic
progenitors. Edil3-/- osteoblastic progenitors exhibited a limited ability in forming
calcified nodules (Fig.7A). Consistently, this mineralization deficiency was
restored by supplying DEL-1-Fc (2µg/ml) every three days in the osteogenic
medium in comparison with Fc control (0.62µg/ml). Treatments with DEL-1-Fc
mutants used at the same molar concentration DEL-1 showed that the Edil3-/progenitors treated with DEL-1[RGE]-Fc failed to generate calcified nodules, but
the progenitors treated with DEL-1[E1-3]-Fc could form calcified nodules as when
treated with intact DEL-1-Fc. Further examination on the osteogenic markers
showed that the N-terminal part of DEL-1 upregulated osteogenic genes, Runx2
and Bglap, and facilitated osteogenic differentiation in an RGD-dependent manner
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(P<0.05 vs. Fc control; Fig.7B). These in vitro experiments further support our
findings in vivo and indicate that DEL-1 promotes bone regeneration during
resolution through directly regulating osteogenic differentiation on osteoblastic
progenitors.
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Figure 7. DEL-1 promotes osteoblast differentiation through its RGD motif. Primary
osteoblastic progenitor cells were isolated from the calvariae of 3-day-old Edil3+/+ and
Edil3-/- mice. The isolated progenitors were cultured in osteogenic differentiation medium
in the presence or absence of intact DEL-1-Fc (2 μg/ml) or equal molar amounts of Fc
control or mutants. (A) Representative mineralized nodules detected with Alizarin Red S
staining on day 18 of differentiation. (B) The quantified mineralization at day 18, and (C)
the expression of osteogenic regulated by DEL-1-Fc or mutants were compared at 12
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days of differentiation. Upper and lower panel indicated for the osteogenic markers
expressed from Edil3+/+ and Edil3-/- progenitors, respectively. Data are means ± SD (n=4
cultures per group). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, NS, not significant
(one-way ANOVA and the Dunnett’s multiple-comparison test).
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3.5 DEL-1 interacts with β3 integrin on osteoblastic progenitors to
promote mineralization.
To determine the receptor(s) DEL-1 may use to promote osteogenic differentiation,
we performed pull-down assay through binding poly-histidine-tagged DEL-1-Fc
onto the polyHis pull-down column and incubated with cell membrane lysate
isolated from the murine osteoblastic progenitor cell line (MC3T3-E1 subclone 4).
The pull-down results revealed that DEL-1 preferentially interacted with β3 but not
β1 integrin on osteoblastic progenitors (Fig.8A). To confirm whether DEL-1
promotes osteoblasts mineralization through a β3 integrin-dependent manner, we
stably inhibited β3 integrin expression using Itgb3 shRNA in MC3T3-E1 cells
(P<0.0001 vs. control shRNA; Fig.8B). In MC3T3-E1 cells, DEL-1-Fc induced the
expression of the master transcription factor Runx2, and Bglap (Osteocalcin),
typical early, and late osteogenic markers respectively (P<0.05 vs. Fc control;
Fig.8C); however, these upregulatory effects of DEL-1-Fc were abrogated in β3
integrin shRNA-transfected cells (P>0.05 vs. Fc control; Fig.8C). Using the abovementioned mineralization assay, we further confirmed that the ability of DEL-1 to
promote mineralization was abolished in Itgb3 knockdown transfectants (P>0.05
vs. Fc control; Fig.8D).
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Figure 8. DEL-1 promotes osteoblast mineralization through β3 integrin-dependent
mechanism. (A) PolyHis pull-down assay was performed using polyhistidine-tagged DEL1-Fc (100µg) bound to the cobalt-chelate resin column. Cell membrane protein lysates
from MC3T3-E1 cells (1 x107 cells) were loaded into the DEL-1-Fc-bound column, and the
interacted proteins were eluted with imidazole and resolved using SDS-PAGE followed by
immunoblotting with antibodies to the indicated molecules. Lysates represent 10% input.
MC3T3-E1 cells were further transfected with control versus β3 knockdown shRNA. (B)
The knockdown of β3 integrins was confirmed by immunoblotting. (C) MC3T3-E1 cells
were cultured in osteogenic medium in the presence of DEL-1-Fc (2g/ml) or Fc control
(0.62 g/ml). The cells were analyzed for the expression of Runx2 (at day 6), Bglap (at
day12). (D) Representative images of Alizarin Red S staining, and the quantified
mineralization results. Data of mRNA expression level were normalized to those of Gapdh
mRNA and expressed as fold change in transcript level relative to control shRNA-treated
cells, which were assigned an average value of 1. Data are means ± SD (n= 4-6 cultures
per group). **P < 0.01, ***P < 0.001, not significant (two-tailed unpaired t-test).
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Chapter 4. Discussion and Conclusion
4.1 DEL-1 as a novel osteogenic factor: Implications and future
directions
While the murine periodontal resolution model has been previously developed to
interrogate the mechanism by which DEL-1 promotes inflammation resolution
(Kourtzelis et al., 2019), the current model has been further developed to
investigate the ability of DEL-1 to mediate a novel function during inflammation
resolution, namely bone regeneration. Our findings show for the first time that DEL1 promotes formation of new alveolar bone during resolution of experimental
periodontitis in mice. Mechanistically, we showed that DEL-1 promotes
osteoblastic differentiation by acting via its RGD motif on β3 integrin in
osteolineage progenitors.
Since regulating inflammation may also have a profound effect on bone
formation, the possibility that DEL-1 may indirectly promote bone formation during
resolution through its anti-inflammatory effect cannot be ignored. DEL-1 has been
shown to regulate inflammation through at least two distinct mechanisms: inhibiting
neutrophil recruitment to infected or inflamed tissues (Choi et al., 2008; Eskan et
al., 2012) and promoting efferocytosis (Kourtzelis et al., 2019). The latter
mechanism contributes critically to inflammation resolution and is thus likely to
secondarily enhance osteoblast function and bone formation (Matzelle et al.,
2012). However, we have conclusively shown that DEL-1 can have direct effects
on osteogenesis. First, DEL-1(E1-3)-Fc, which lacks the C-terminal discoidin-like
domains, successfully promoted in vivo bone regeneration in our model (Fig.6),
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whereas it failed to promote efferocytosis (Kourtzelis et al., 2019). Second, DEL-1
in vitro was capable of promoting the differentiation of osteoprogenitors into
osteoblastic cells with mineralization capacity. Consistently, both the abovementioned in vivo and in vitro activities of DEL-1 were absolutely dependent upon
its integrin-binding RGD motif and the interactive partner on osteoprogenitors is
likely the β3 integrin. An earlier study, which also used MC3T3-E1 osteoprogenitor
cells, an established model of osteoblast differentiation and function (Addison et
al., 2015; Quarles et al., 1992), implicated α5β1 integrin as the DEL-1 receptor (Oh
et al., 2017). However, the authors found that DEL-1-induced matrix mineralization
was inhibited equally well by antibodies to either β1 or β3 integrin.

A future

experiment utilizing osteoblastic lineage-specific β3 integrin knockout mice may
conclusively implicate this integrin as the DEL-1 receptor in osteoprogenitors. If
injecting DEL-1-Fc fails to promote bone regeneration in these conditional
knockout mice, one may conclude that bone regeneration is contributed by the
direct effect of DEL-1 on β3 integrin in osteoblastic lineages.
The association between DEL-1 and osteogenesis has been previously inferred
by genetic (Layh-Schmitt et al., 2017) and proteomic (Rose-Martel et al., 2015)
mineralization screenings. The osteogenic effect of DEL-1 is also consistent with
relevant studies on another glycoprotein, the milk-fat globule-epidermal growth
factor 8(MFG-E8), which is structurally similar to DEL-1 (MFG-E8 and DEL-1 both
contain two discoidin-like domains and RGD motif, although DEL-1 has three EGF
domains and MFG-E8 only two). Indeed, deficiency of MFG-E8 in mouse
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osteoblastic progenitors resulted in compromised bone formation in vivo and in
vitro (Sinningen et al., 2015). While the RGD motif of DEL-1 and MFG-E8 has
been shown to bind to αvβ3 integrin in different cell types, direct evidence for
interaction with αvβ3 integrin on osteoblastic progenitors has been shown for DEL1 only, in our present study. In this regard, our pull-down assay indicated a direct
interaction of DEL-1 with β3 on osteogenic progenitor (MC3T3-E1) cells. Another
research group has also shown that DEL-1 can induce Runx2/ERK signaling
pathway to induce osteogenic differentiation in MC3T3-E1 cells (Oh et al., 2017).
The periodontal ligament (PDL) contains a heterogeneous mesenchymal
stromal and stem cell (MSC) population which is involved in periodontal tissue
regeneration, including the extracellular matrix and adjacent mineralized tissues
such as the alveolar bone. Multipotent stem cells in the PDL can differentiate into
distinct lineages including osteoblasts that form alveolar bone (Bassir et al., 2016;
Fournier et al., 2013; Ren et al., 2015; Seo et al., 2004; Washio et al., 2010;
Yamamoto et al., 2014). Future studies can address whether DEL-1 in the PDL
regulates the MSC niche to promote bone regeneration and to identify the
underlying mechanisms. In this regard, DEL-1 was shown to regulate the bone
marrow stem cell niche. Specifically. DEL-1 was shown to be a crucial regulator of
the hematopoietic stem cell niche (HSC) niche, i.e., the supportive microanatomical environment in the bone marrow where HSCs reside. In the HSC
niche, DEL-1 is expressed by arteriolar endothelial cells, cells of the osteoblastic
lineage and a specialized mesenchymal stromal cell (MSC) type, the CXCL12abundant reticular cells (Mitroulis et al., 2017a). Similar to our studies presented
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here, DEL-1 was shown to interact with β3 integrin on HSCs and to promote their
proliferation and myeloid differentiation (Mitroulis et al., 2017b).
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4.2

Application of current work to the clinical periodontal therapy

The physiological upregulation of DEL-1 and its novel osteogenic property
during resolution of periodontitis renders DEL-1 an ideal biomarker to monitor and
predict patient’s response during reevaluation phase of periodontal therapy. This
concept has been successfully demonstrated in our recent work in which the
upregulation of DEL-1 can be detected in gingival crevicular fluid (GCF) of patients
following periodontal therapy (scaling and root planing) (Kourtzelis et al., 2019).
Further application of DEL-1 as a pro-resolution and osteogenic protein drug may
be suitable to apply in specific patient populations (such as the elderly), in which
poor resolution response to the scaling and root-planing as well as lower level of
DEL-1 in GCF is detected, as customized precision medicine to restore functional
bone regeneration in these patients.
Most of the current periodontal regenerative strategy requires surgical
intervention so that a direct application of osteoinductive protein drug (such as
BMP2, PDGF-BB, and Enamel Matrix Derivatives) on the root surface may be
feasible. However, such kind of surgical strategy underestimates the regenerative
potential in our body in which the functional bone regeneration is achievable under
proper homeostatic regulation. The law of bone remodeling, commonly referred to
as Wolff’s law, asserts that the internal trabecular bone adapts to the external
loadings, reorienting with the principal stress trajectories to maximize mechanical
efficiency creating a naturally optimum structure (Boyle and Kim, 2011), in which
“the remodeling of the bone occurs in response to physical stress or lack of stress”
(Oppenheimer et al., 2008; Wolff, 1986). As cervical periodontal ligaments and
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fibers play critical role in mediating the principal occlusal stress to alveolar bone
(Nomoto et al., 2006; Saffar et al., 1997), transplanting tooth with intact cervical
periodontal fibers further regenerates crestal bone in periodontal defect while
transplanting tooth with defective cervical periodontal fibers result in crestal bone
loss in the previous study (Polson and Caton, 1982). The traditional periodontal
bone-grafting surgery apply the bone graft to the periodontal bony defect in crestal
stress bearing area; however, this procedure is against to Wolff’s law because any
bone graft interrupts the stress trajectories will be prone to resorption
(Oppenheimer et al., 2008), besides, the periodontal incisions during bone-grafting
surgery unavoidably dissect or remove cervical periodontal fibers which may
interrupt the distribution of the occlusal force and contribute to crestal bone loss
(Carnevale and Kaldahl, 2000; Nomoto et al., 2006; Pfeifer, 1965; Wood et al.,
1972). In comparison with traditional bone-grafting surgery, local injection of DEL1 provides an osteogenic strategy without interrupting the load-bearing structure
of pre-existing cervical periodontal fibers. Through the comparison of local
injecting Fc control or DEL-1-Fc in Edil3-/- mice, we have demonstrated that DEL1 injection regenerates the crestal tooth-supporting bone in the context of
resolution and restore similar functional tissue structure to its DEL-1-sufficient
littermate. This physiological bone regenerating strategy may allow regenerating
the functional structure of periodontal bone in the patient with insufficient of DEL1 and reduce the need for bone-grafting periodontal surgery.
The proposed pro-resolving DEL-1 therapeutic strategy for periodontitis is
intended to be applied as a complementary approach to augment the therapeutic
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effect following the standard phase I periodontal therapy (i.e. oral hygiene
instruction, scaling and root planing. Interestingly, DEL-1 promotes the production
of certain resolvins (e.g. RvD1 and RvE1) during inflammation resolution in
periodontitis (Kourtzelis et al., 2019). Reciprocally, resolvins can contribute to the
rising levels of DEL-1 during the resolution of inflammation, for instance, by
counteracting inhibitory mechanisms that would otherwise suppress DEL-1
expression (Maekawa et al., 2015). Moreover, DEL-1 is a non-redundant effector
of inflammation resolution acting downstream of resolvins (Kourtzelis et al., 2019).
Together, these findings suggest the operation of a positive feedback loop that
connects DEL-1 and resolvins and reinforces inflammation resolution. As the
traditional plaque control strategy has been well-established for most periodontitis
patients, DEL-1 therapy applied on top of plaque control may further improve
treatment quality through facilitating resolution of inflammation and functional
tissue regeneration.
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4.3

Conclusion

Our findings support the notion for a direct effect of DEL-1 in promoting
osteoblastogenesis and formation of new bone through a β3 integrin dependent
mechanism. Whereas intact DEL-1 is required for efferocytosis and the emerging
of pro-resolving macrophages (Kourtzelis et al., 2019), the RGD-containing Nterminal part of DEL-1 is sufficient to promote osteogenic differentiation and bone
regeneration. In conclusion, DEL-1 is shown for the first time to promote bone
regeneration during resolution of periodontitis, a function that may be adjunctively
exploited in combination with the current periodontal therapy to facilitate bone
regeneration during resolution of human periodontitis.
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Chapter 5. Translational Application of the Research
5.1. Introduction
5.1.1 The current hurdle of regenerative periodontal therapy
More than 30 years have passed since the first successful application of
regenerative therapy for the treatment of periodontal diseases (Lin et al., 2015).
Despite being feasible, a complete restoration of structure and function of diseased
periodontium is still an unpredictable task and the relevance of comparing costs
and outcomes of periodontal treatment has increasingly and repeatedly been
emphasized in the periodontal literature (Braegger, 2005; Cochran et al., 2015;
Listl and Birch, 2013; Pennington et al., 2011; Pennington et al., 2009). While the
health care resources (such as dentists and dental assistant’s time, surgical
instruments, diagnostic equipment, and regenerative materials to be applied) are
limited, doctors are forced to make the best use of those resources to compose a
treatment plan within patient’s affordability which limits the availability of optimal
treatment outcome. Although the rapid advance in medical technology often leads
to a more effective treatment option, such option often involves higher costs than
existing therapeutic approaches and piles up the treatment cost. Hence,
developing an effective, efficient, yet affordable treatment strategy is a critical and
unmet need for translational periodontal research.
Historically, periodontal regeneration has focused on applying barrier
membrane and scaffold such as bone substitutes to provide for defect fill and
selected cell repopulation of the lesion (Cochran et al., 2015). Over the past two
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decades, numerous studies have explored the potential of using biologic proteins
and peptides in periodontal regeneration, and several have been approved for
clinical use (Lin et al., 2015). While emerging studies continuously discover new
protein candidates for their pharmaceutical application in customized periodontal
regeneration and precision medicine, the expense of protein synthesis,
purification, and preservation had piled up the cost of these therapeutic strategies.
However, a precision medicine cannot be precise enough if the patient who need
it cannot afford for the treatment. A novel strategy in protein drug synthesis,
preservation and delivery remains unavailable from the market. Recent advance
in biopharmaceutical research has developed the technique to reduce the cost of
protein drug manufacturing through genetic modification on the chloroplasts to
synthesize pharmaceutical proteins.

5.1.2 Chloroplast as a bioreactor for affordable protein drug synthesis
Chloroplasts are one of the ultimate symbiotic collaboration between prokaryotic
microbe (cyanobacteria) and its eukaryotic host (plant cells). This collaboration
eventually sustains life on earth by converting solar energy to carbohydrates
through the process of photosynthesis and oxygen release (Daniell et al., 2016).
Beyond photosynthesis, chloroplasts also play several critical roles in plant
physiology and development, including synthesis of amino acids, nucleotides,
phytohormones, fatty acids and production on some multitude of secondary
metabolites and the sulfur and nitrogen assimilation (Pfannschmidt and Yang,
2012). Chloroplasts possess their own genomes, ribosomes, tRNAs and protein
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synthetic machinery; they also import thousands of nuclear encoded proteins
synthesized in the cytoplasm (Daniell et al 2016 A, B). Chloroplast genome
contains operons like prokaryotes but also several types of introns like eukaryotes.
Thus, chloroplasts possess both prokaryotic and eukaryotic features.
During evolution, hundreds of genes of the endosymbiont have been
transferred to the host nuclear genome (Chen et al., 2018); thus most chloroplast
proteins are synthesized in the cytosol and imported into the chloroplast for selfassembly or along with subunits synthesized by the chloroplast genome (Daniell
et al 2016 A, B). This unique collaboration makes chloroplast a specialized
organelle for protein synthesis, folding and several posttranslational modifications
(PTMs) in plant cells. Specifically, the endogenous disulfide transferase in
chloroplast can facilitate protein folding and stabilize the tertiary structure to
maintain the proper functional protein confirmation (Zhang et al., 2017). On the
other hand, recent studies also reveal that chloroplast can perform several PTMs
such as phosphorylation, acetylation, methylation, and may be able to collaborate
with endoplasmic reticulum (ER) and Golgi apparatus to achieve N-glycosylation
via vascular Golgi-to-plastid transport pathway (Kitajima et al., 2009; Lehtimaki et
al., 2015; Zhang et al., 2017). The independence of chloroplast genome and
maternal inheritance characteristic makes chloroplast an ideal bioreactor for a low
cost and rapid scale-up biopharmaceutical production, and minimizes the concern
of outcross of introduced foreign genes (Daniell, 2007). While biologically active
enzymes and vaccines generated by this technique has been shown to be
functional despite keeping in room temperature, this innovative protein synthesis
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strategy provides an ideal platform in translating active periodontal regenerative
protein into affordable regenerative treatment modality.
As DEL-1-Fc has been shown to be an effective protein drug to restrain IL17-associated bone loss in non-human primates (Shin et al., 2015), the current
study further confirms its potential in promoting bone regeneration during
inflammation resolution. However, the ultimate goal of our scientific work is not just
to provide effective medicines that improve current treatment, but also to make it
affordable so that the majority of the patient in need could benefit from it. Thus, at
the end of this thesis, we performed a translational study by sub-cloning DEL-1-Fc
sequence into chloroplast vectors and aiming to transform the lettuce chloroplast
genome to generate genetically modified plants expressing DEL-1-Fc so that
periodontitis patients may benefit from this research.
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5.2 Materials and Method
5.2.1 Subcloning DEL-1-Fc plasmid targeting lettuce chloroplasts
To target the lettuce chloroplast for DEL-1-Fc protein expression, we developed a
plan to insert DEL-1-Fc sequence into the lettuce-chloroplast targeting plasmid
(pLs-MF). The pLs-MF backbone vector was previously constructed by Henry
Daniell’s laboratory (Daniell et al., 2019; Kumari et al., 2019) which contains the
lettuce chloroplast genome flanking sequences including partial 16S (16S rRNA),
isoleucine tRNA(trnl), alanine tRNA(trnA) genes, and partial 23S (23S rRNA) to
facilitate homologous recombination of the transgene cassette into native lettuce
chloroplast genomes (Fig.9). The unique expression cassette of the pLs-MF
contains a pair of direct repeat atpB sequences (649 bp) flanking the aadA
selection marker gene (encoding aminoglycoside 3’-adenylyltransferase) to confer
initial spectinomycin selection and later on marker gene excision (Daniell et al.,
2019; Kumari et al., 2019).
The original sequence of DEL-1-Fc was acquired from a pSecTag2-DEL-1-Fc
plasmid constructed by George Hajishengallis’s laboratory (Choi et al., 2008). This
DEL-1 plasmid (pSecTag2-DEL-1-Fc) included nucleotides for 6 histidine
sequences at its 3’ end so that this His-tagged recombinant protein could be further
purified by Ni-NTA column. However, for the translation propose, in order to
accommodate the regulation from Food and Drug Administration (FDA), that
antigenic epitope should be removed to avoid potential immunogenic reaction.
Thus, the His-tag was removed from Del1-Fc using a reverse primer covering the
54

3’ end of Fc sequence, as well as the stop codon and restriction site suitable for
sub-cloning. The DEL-1-Fc insert was amplified by using specific primer sets to
create the restriction sites suitable for insertion into pLS-MF (Daniell et al., 2018).
In brief, the DEL-1-Fc insert was amplified with forwarding primer (5’- ATT TTA
CAT ATG AAG CGC TCG GTA GCC -3’) containing NdeI cutting site and reverse
primer (5’- CAA TAA GAC CAA AGT CTC TAG ATC ATT TGC CCG GGC TCA
GGC T -3’) containing PshAI cutting site (Fig.10). The 3’ end of DEL-1-Fc insert
was further extended by overlapping PCR (Kwon et al., 2018) to create NotI cutting
site using additional reverse primer (5’- CAG CCA CCG CGG TGG CGG CCG
CTT TC -3’) followed by complete digestion on NotI and partial digestion of NdeI
restriction enzymes, respectively. The high-fidelity polymerase (#M0491S, NEB)
was applied to the abovementioned PCR reactions to avoid mutations when
amplifying insert.
For subcloning of DEL-1-Fc into the lettuce marker-free chloroplast vector
pLs-MF, it was digested with NdeI (#R0111S, NEB) and NotI (#R0189S, NEB)
restriction enzymes, respectively. DEL-1-Fc fragment was further sub-cloned into
the linearized vector using NEBuilder® HiFi DNA Assembly (#E5520, NEB). The
constructed plasmid was then transformed into TOP10 E. coli cell and selected on
the Lennox LB broth agar plate with spectinomycin (100 mg/L) overnight (Kwon et
al., 2018). Screening for recombinant plasmids was done by colony PCR
(Bergkessel and Guthrie, 2013; Verma et al., 2008) using forward (5’- CAA GCC
TTT AGT TTT CCA TTT GAA AAT TCG TGC GC -3’) and reverse (5’- TTT CTG
AAA TCA AA GA A ATA AAT AAT AAA AAT TTT CAT TTT TAT CT -3’) primers.
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The positive clones were further cultured in 5ml of ampicillin-containing (100 mg/L)
LB broth (Lennox) medium overnight. The plasmids were extracted by the alkaline
lysis method (Green et al., 2012) to confirm the presence of the appropriate
insertion by restriction enzyme digestion map using PstI (#R0140S, NEB) and
PvuII (#R0151S, NEB) dual cutting enzymes. The DEL-1 protein expression from
double positive clones was further confirmed by western blots using monoclonal
rabbit anti-human DEL-1 antibody [ab190692, Abcam]. The sequence on both
ends of the expression cassette (pLs-MF-DEL-1-Fc) was confirmed by Sanger
sequencing using the forward (5’- CAA GCC TTT AGT TTT CCA TTT GAA AAT
TCG TGC GC -3’) and reverse (5’- TTT CTG AAA TCA AAG AAA TAA ATA ATA
AAA ATT TTC ATT TTT ATC T -3’) primers, respectively. Finally, the sequenceconfirmed plasmids were transformed into TOP10 E. coli cell and extracted using
PureYieldTM Plasmid Miniprep System (Promega, Madison, WI).
5.2.2 Fc-Based Receptor-Binding Functional assay
To confirm protein function before transforming to lettuce, a receptor-binding
immunoprecipitation assay was performed. Overnight cultured E. coli cells in
ampicillin and spectinomycin (100mg/L) -containing Lennox LB broth medium
(#BP1427-500, Fisher Scientific) were pelleted, re-suspended in 4ml of extraction
buffer (#78248, Thermo Scientific) containing 8μl of lysozyme (L-6876,Sigma) and
8μl of DNase I (#4716728001, Sigma) and 20mg of EDTA-free protease inhibitor
(#A32955, Thermo Scientific) per gram of cell pellet and incubate at room
temperature for 15 minutes to break down cells. The cell lysate was further
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centrifuged at 15,000 x g for 5 minutes to separate soluble proteins from the
insoluble proteins and performed western blot to identify which component
contains DEL-1-Fc protein. After identifying the DEL-1-Fc in the insoluble portion
(inclusion body) (Fig.13A), the insoluble proteins were further dissolved by
inclusion body solubilization reagent (# 78115, Thermo Scientific), and dialyzed in
1L of 6M urea with 5mM DTT in 4oC for 24 hours and refolded in vitro by adding
250ml of 25mM Tris-HCL (pH 7.5) every 12 hours until the final volume become
3L. Finally, the dialysis solution was replaced with 25mM Tris-HCl (pH 7.5) and
150mM NaCl for another 6 hours to elute the protein. After elution, the refolded
proteins (50 µg) were first mixed with the protein-G conjugated magnetic beads
(10003D, Invitrogen) at 4oC for 2 hours, and then transfer to the magnetic
separation rack (7017, CST) to purify the refolded DEL-1-Fc utilizing the affinity of
its Fc component with Protein G. The protein G-purified DEL-1-Fc as well as same
amount of negative control protein (50 µg, human IgG-Fc, AG714, Millipore) and
positive control protein (50 µg, human cell-derived DEL-1-Fc) were further reacted
with the 50μg of cell-membrane protein isolated from human gingival-derived
mesenchymal stem-like cells (hGMSC) which was isolated by cell fractionation kit
(#9038, CST). The immunoprecipitated complex was then washed by RIPA buffer
four times and re-suspended with 1x Laemmli buffer. The unreacted total protein
was also collected and re-suspended with 1x Laemmli buffer. All buffer-containing
samples were heated at 70o C for 15 minutes and loaded in SDS-PAGE for western
blot.
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Figure 9. Maps of the Lettuce chloroplast genome and pLs-MF-DEL-1-Fc markerfree chloroplast vector. A. Map of lettuce (Lactuca sativa) chloroplast genome
(accession number: AP007232). The dark and light blue marked the location of trnA and
trnI genes, respectively. B. Marker-free chloroplast vector DEL-1-Fc: All components of
the lettuce marker-free chloroplast vector were previously developed in the Daniell
laboratory (Daniell et al., 2019; Kumari et al., 2019).

The trnA and trnI genes are

respectively shown in dark and light blue; the inverted repeat sequences of the atpB gene
are shown in red; the aadA and blaTEM genes are shown in yellow and orange for
spectinomycin and ampicillin resistance genes, respectively. The DEL-1-Fc gene is shown
in green, and the restriction sites used for sub-cloning shown on the plasmid map. The
Prrn and PpsbA are chloroplast promoters; the Trbcl and TpsbA at 3’ end of the aadA and
DEL-1-Fc genes are 3’UTRs. STOP shows the stop codon. The lettuce chloroplasts
genome map was originally developed in this thesis using OGDRAW online software
(https://chlorobox.mpimp-golm.mpg.de/OGDraw.html) using lettuce chloroplast sequence
downloaded from NCBI database. The plasmid map was developed using SnapGene
software ( https://www.snapgene.com/ ).
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Figure 10. Cloning strategy for constructing DEL-1-Fc plasmid (pLs-MF-DEL-1-Fc)
targeting chloroplast in lettuce. The DEL-1-Fc fragment (2,163 bp) was amplified with
forward primer containing NdeI cutting site and reverse primer containing PshAI cutting
site. The 3’ end of DEL-1-Fc insert was further extended by overlapping PCR (OLPCR) to
approach NotI cutting site using additional reverse primer, followed by a complete
digestion on NotI and a partial digestion of NdeI restriction enzymes, respectively. The
pLs-MF vector was digested with NdeI and NotI to yield the insert fragment: PpsbA and
TpsbA using NdeI and NotI. DEL-1-Fc insert (2,576 bp).
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5.3

Results

5.3.1 Subcloning of pLS-MF-DEL-1-Fc plasmid
The constructed plasmid was evaluated using previously established protocol
(Verma et al., 2008) in which putative clones were screened by colony PCR
(Bergkessel and Guthrie, 2013; Verma et al., 2008), restriction enzyme digestion
maps (Verma et al., 2008), and the expressed protein size using western blot
(Kwon et al., 2018) (Fig.11). After digesting the vector and insert with the restriction
enzyme, a vector fragment without insert was also transformed into competent
cells as a negative control to rule out potential carry-over of undigested backbone
plasmid (Fig.11A). One out of 28 positive clones obtained from spectinomycin
(100μg/mL), selection plate shows the predicted band size (2,281bp) under the
screen of colony PCR (Fig.11B). The positive clone was further amplified in
Lennox LB broth medium containing ampicillin (100μg/mL). The plasmid was
further extracted and digested with restriction enzymes PstI and PvuII (Fig.9B).
The PstI enzyme digested both in the middle and the 3’end of DEL-1-Fc sequence,
creating the fragments of 1,474 bp and 10,038 bp; on the other hand, the PvuII
enzyme digested at the end of Trbcl and in the middle of DEL-1-Fc sequence,
creating the fragments of 1,480 bp and 10,032 bp (Fig.11C). After confirming by
enzyme digestion, the recombinant protein in the positive clone was further
extracted for western blot analysis. The total cell-lysate from the untransformed
competent cells (Top10 E. coli) and competent cells transformed with original DEL1 plasmid (pSecTag2-DEL-1-Fc) were included as the negative and positive
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control of DEL-1 expression, respectively (Fig.11D). Potential nonspecific binding
of the monoclonal rabbit-anti-human DEL-1 antibody was identified between 75
and 100 kDa in the untransformed cell-lysate while possible true-positive signal
between 50 and 75 kDa was observed in cells transformed with original DEL-1
plasmid (pSecTag2-DEL-1-Fc). The DEL-1-Fc expressed from the positive clone
(pLs-MF-DEL-1-Fc) was strongly detected at the same size as detected in the
positive control.
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Figure 11. Evaluate the constructed plasmid. A. The competent cells transformed with
digested vector without or with insert fragment were applied on the plate containing
spectinomycin(100μg/mL). The outgrowth clones were marked and picked up for colony
PCR screening. B. The colony PCR screening revealed one positive clone with the
amplified band close to the predicted size indicated by the red arrow (2,281bp). L: 1kb
DNA ladder (#N3232L, NEB). C. The undigested plasmid and the plasmid digested by PstI
or PvuII were compared on the electrophoresis gel. The predicted bands were identified
under PstI (1,474bp; 10,038bp) or PvuII (1,474bp; 10,038bp) enzyme digestion,
respectively. D. The western blot revealed strong expression of recombinant DEL-1-Fc on
the size similar to the positive control (indicated by red arrows).
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5.3.2 Sanger sequencing confirms seamless integration of DEL-1-Fc
sequence into pLs-MF plasmid
The internal fragment between PstI restriction sites on the positive clone was
removed and inserted with the corresponding fragment digested from the original
DEL-1 plasmid (pSecTag2-DEL-1-Fc) to avoid mutations during PCR amplification
(Fig.12A). The re-ligated plasmid was further transformed into competent cells and
the outgrowth clones were screened and picked-up for Sanger sequencing using
forward and reverse primers on the backbone (pLs-MF) vector. The forward
sequencing validates the junction between PpsbA and DEL-1 gene, and an intact
5’PstI restriction site (Fig.12B). The reversed sequencing validates the junction
between TpsbA and IgG Fc gene as well as intact 3’PstI restriction site (Fig.12C).
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Figure 12. Sequencing result indicated no mutation was introduced. A. The internal
fragment between PstI restriction sites on the constructed plasmid (pLs-MF-DEL-1-Fc)
was replaced by the corresponding fragment on the original DEL-1 plasmid (pSecTag2DEL-1-Fc). B. The forward sequencing validates the junction between PpsbA and DEL-1
gene, and an intact 5’PstI restriction site. C. The reversed sequencing validates the
junction between TpsbA and IgG Fc gene as well as intact 3’PstI restriction site.
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5.3.3 Identify and purify E. coli-derived DEL-1-Fc protein from inclusion
body
To interrogate whether the constructed protein may have a biological function, the
E. coli-derived DEL-1-Fc was further extracted for functional assay. However, after
comparing the protein extracted from the whole cell homogenate, supernatant, and
insoluble cellular debris in the pellet, we found most of the recombinant DEL-1-Fc
protein expressed in E. coli was in the insoluble pellet fraction, indicating the
potential aggregation in the inclusion body (Fig.13A). After resolubilizing and
refolding the protein aggregates from the inclusion body, the refolded DEL-1-Fc
was further purified through specific binding affinity of its Fc component to the
protein-G beads (Fig.13B).

5.3.4 Utilizing immunoprecipitation to interrogate receptor-protein
interaction
To interrogate whether the DEL-1-Fc derived from prokaryotic system may serve
similar receptor binding function as the human cell-derived DEL-1-Fc, we further
developed an in vitro receptor-binding assay to interrogate this concept. The
Protein G-purified DEL-1-Fc was further mixed with the cell membrane proteins
extracted from human gingival-derived mesenchymal stem-like cells (hGMSC) to
allow receptor-ligand immunoprecipitation (Fig.13B). Utilizing the recombinant
human IgG-Fc as negative control and human cell-derived DEL-1-Fc as positive
control, we further found that prokaryote-derived DEL-1-Fc (generated by pLS-MFDEL-1-Fc plasmid in E coli) may serve similar receptor-binding function as those
derived from human cells (Fig.13C). Similar to the MC3T3-E1 cells, a basal level
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of endogenous DEL-1 (52kDa) was also detected on the hGMSC cell membrane
and the preferential interaction of DEL-1-Fc to β3 integrin (but not to β1 integrin)
was also observed in both human and E coli-derived DEL-1-Fc. The negative
control (IgG Fc) does not precipitate the β3 integrin receptor suggesting that the
observed β3 integrin binding function from prokaryote-derived DEL-1-Fc may be
specific.
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Figure 13. Functional assay for prokaryote-derived DEL-1-Fc protein. A. Specific
DEL-1 signal was identified through the comparison between total cell-lysate derived from
untransformed and pLs-MF-DEL-1-Fc transformed competent cells. The comparison
between total cell-homogenate, soluble supernatant, and insoluble pellet indicated most
non-specific E. coli proteins that react with monoclonal DEL-1 antibody were kept in the
supernatant, while most of the recombinant DEL-1-Fc proteins were retained in the
insoluble pellet. B. The crude DEL-1-Fc protein recovered from the pellet were purified by
the Protein-G magnetic beads and performed immunoprecipitation with the 50μg of cell
membrane proteins (receptors) isolated from human gingival-derived mesenchymal stemlike cells (hGMSC). C. Comparison of receptor-binding function between 50μg of crude
proteins containing prokaryote (E coli)-derived DEL-1-Fc, human IgG-Fc (negative
control) and human cell-derived DEL-1-Fc (positive control) on the receptor between the
recombinant DEL-1-Fc to the β3 integrin and β1 integrin.
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5.4

Discussion

Chloroplast transformation technology (CTT) has been developed more than 30
years and has multiple pharmaceutical applications aiming on the treatment of
hemophilia (Herzog et al., 2017; Kwon et al., 2018; Su et al., 2015), pulmonary
hypertension (Shenoy et al., 2014), diabetes (Boyhan and Daniell, 2011; Kwon et
al., 2013; Posgai et al., 2017) and vaccination (Chan et al., 2016; DavoodiSemiromi et al., 2010). While many traditional biopharmaceutics was produced by
tobacco (Liu et al., 2016; Xiao et al., 2016b) and some of them contains polyhistidine tags (Arlen et al., 2007; Koya et al., 2005) for the benefit of large biomass
production and for the ease of protein purification, the potentially addictive nature
of tobacco (due to its nicotine content) and the potential antigenic effect of the polyhistidine tags have limited its clinical application. The currently constructed pLsMF-DEL-1-Fc plasmid utilizing the latest strategies in Dr. Henry Daniell’s
laboratory to conquer the above mentioned concerns: First, the plasmid was
specifically designed for transforming the lettuce chloroplast to avoid the potential
side effect from tobacco; second, the current plasmid has removed the polyhistidine tag to avoid the antigenic effect, the histidine tag-based purification step
can be replaced by the affinity purification utilizing the Fc component of DEL-1-Fc
which binds to protein A/G and other materials following the well-established
process for the purification of commercially available monoclonal antibodies (Choe
et al., 2016). In addition, the currently designed plasmid targets the trnI, and trnA
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genes within both inverted repeat regions on lettuce chloroplast genome (Fig.9A)
which doubles the expression per chloroplast once the homoplasmy is achieved.
The PsbA promoter (PpsbA) engineered on the current pLs-MF-DEL-1-Fc
construct has been shown to be a more efficient promoter in hyper-expression of
foreign protein in E. coli in comparison with traditional T7 promoter (Brixey et al.,
1997), which may explained the observed hyperexpression of DEL-1 signals in
pLs-MF-DEL-1-Fc plasmid in comparison with the original (pSecTag2-DEL-1-Fc)
plasmid (Fig.11D). On the other hand, while the DEL-1 is a glycoprotein originally
produced in a eukaryotic system, lack of glycosylation in E. coli or chloroplast
raises a concern on structure or function of Del1. Although the functional
comparison between un-glycosylated and glycosylated DEL-1 protein has not yet
been fully investigated, one recent study found the pro-resolution activity of MFGE8, a protein shares 70% structure similarity with DEL-1, proportionally decreased
by the increased glycosylation under hyperglycemic condition, suggesting the unglycosylated DEL-1 may have a better pro-resolution function (Das et al., 2016).
Our immunoprecipitation result (Fig.13C) further suggested that the prokaryote (E.
coli)- derived DEL-1-Fc may preferentially bind to the β3 but not β1 integrin
receptor like the eukaryotic (human)-cell derived DEL-1-Fc (Fig.8A). This receptorbinding immunoprecipitation assay may also be applied in the lettuce-derived DEL1-Fc to interrogate its function.
While the E. coli-derived DEL-1-Fc protein was recovered from the insoluble
protein aggregates (inclusion bodies), it raises a concern regarding structural
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differences in the refolded DEL-1 protein. As the structure of DEL-1 contains 12
disulfide

bonds,

2

O-glycosylation

and

1

N-glycosylation

(http://www.uniprot.org/uniprot/O43854), the complex structure may heavily rely
on the post-translational modification for proper folding. However, as Anfinsen’s
experiment indicated (Anfinsen, 1973; Fernandez-Reche et al., 2018), the
sequence of the peptide dictated the information required for the tertiary protein
folding thermodynamically which partially explains our finding that refolded protein
obtains a specific binding function to β3 but not β1 integrin. This receptor-binding
assay may be further applied as an efficient functional assay which can easily test
the chloroplast-derived protein function to screen for the lettuce clones with optimal
biological function, at least in part.
The fused immunoglobin Fc domain on DEL-1 (DEL-1-Fc) not only serves the
function to increase the plasma half-life of DEL-1 but has also been reported as a
carrier to assist oral drug delivery through the transcytosis event in young mice
intestine utilizing the neonatal Fc receptor (FcRn) (Pridgen et al., 2013; Shi et al.,
2018). The chloroplast-derived protein drug is bioencapsulated by plant cell wall
which can protect from degradation by gastric enzymes/acid and can be released
by cellulolytic microbe in the gut for drug delivery (Kwon and Daniell, 2016).
Utilizing chloroplast as bioreactor for DEL-1-Fc synthesis and delivery may provide
an affordable precision treatment option to improve the homeostatic bone
regeneration in poorly responsive periodontitis patient due to insufficient DEL-1
expression.
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5.4.1 Relationship of current work to periodontal specialty
Aging is an inevitable process which may gradually leads to a scenario of
unresolved inflammation (Arnardottir et al., 2014) and impaired bone regeneration
(Ambrosi et al., 2017). While the current advance in medical technology has
significantly prolonged the lifespan for mankind, an increasing need to improve the
quality of these expanded lives has been underestimated and unmet by traditional
treatment philosophy. Although the goal of periodontal treatment is to preserve or
regenerate the periodontal attachment for the maintenance of periodontal health,
it is also inevitable to have periodontal attachment loss and bone loss with age
(Billings et al., 2018). Thus, establishing a diagnostic system that identifies
endogenous periodontal factors diminished with age and establishing a
supplementary age-associated periodontal treatment strategy will ultimately
improve the quality of life for periodontitis patient. Endogenous DEL-1 in
periodontal tissue has been identified to be diminished with age and contribute to
age-associated periodontal bone loss (Eskan et al., 2012). The first part of this
thesis further identified the upregulation of DEL-1 in periodontal tissue is necessary
for resolving bone regeneration during inflammation resolution (Fig.4F, Fig.5,
Fig.6). While the level of DEL-1 in gingival crevicular fluid (GCF) has been shown
to be associated with periodontal resolution (Kourtzelis et al., 2019), DEL-1 may
become a suitable GCF biomarker to determine aging-associated patient response
during periodontal reevaluation (Tonetti et al., 2018). This chapter further provides
an affordable strategy to replenish DEL-1 which complements the proposed
therapeutic strategy from innovative diagnosis to precision medicine. Benefiting
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from the chloroplast transformation technology, the DEL-1-Fc produced by
transplastomic lettuce will be easy to preserve, affordable to supply and eventually
provide a therapeutic option for the aging-associated poorly resolved periodontitis
patient.
5.4.2 Conclusion
Based on our previous findings in vitro, we successfully established a receptorbinding immunoprecipitation assay to test the function of recombinant DEL-1-Fc in
vitro. This functional assay may be further applied as quality control for the lettucederived DEL-1-Fc to screen for optimal protein quality prior to further application.
This chapter introduces a translational application by transforming DEL-1-Fc into
the chloroplast genome so that an effective, efficient, and affordable pro-resolution
periodontal regenerative treatment strategy may be achieved in the near future.
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Research Limitations
While many conclusions can be drawn from the presented studies, a few limitations
deserve mention. To investigate the resolution mechanism in clinical periodontitis
patients, an ideal intervention studies should be performed on clinical patients or
non-human primates. However, given by the limitation of ethics and research
budget, we establish and utilize a murine periodontal resolution model to
approximate the clinical scenario of periodontal resolution. The fundamental
difference of susceptible microbiota between murine and primates may limit our
ability to make broader generalization from current results. Secondly, although our
in vitro findings suggest DEL-1 have a direct osteogenic effect on osteoblastic
progenitor cells, whether DEL-1 directly contribute to the observed periodontal
resolving bone regeneration through osteogenic progenitors in vivo remains to be
investigated. While resolution of inflammation may have a profound effect on bone
regeneration, whether the RGD motif of DEL-1 contributes to other immune
regulatory mechanism(s) that indirectly promote bone regeneration is still unknown
in the current study. Future experiments using osteoblast (Sp7-Cre)- or osteocyte
(Dmp1-Cre) -specific β3 integrin (Itgb3) conditional knockout mice may allow the
lineage-specific interrogation of DEL-1 to investigate whether DEL-1-promoted
bone regeneration is contributed by it direct osteogenic effect in vivo. Finally, the
cost of manufacturing and purifying high-quality DEL-1-Fc and its mutant proteins
limit the availability of experimental materials for further investigations and clinical
applications. To alleviate this limitation, we provide a novel strategy in Chapter 5
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to reduce the cost of DEL-1-Fc manufacturing using the chloroplast transformation
technology. Nevertheless, as the E coli and chloroplast- derived proteins may
contain certain portions of endotoxins (such as lipopolysaccharide and lipid A)
which may limit their application to endotoxin-sensitive functional assay, current
study using modified receptor-pulldown assay to suggest the potential function of
prokaryote-derived DEL-1-Fc. However, future application using endotoxinremoval assay (#88270, Thermo Scientific) to remove the endotoxin in prokaryotederived DEL-1-Fc may allow for more functional cell- and tissue-specific assay in
vitro and in vivo.
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